Teva and Microchips Biotech Announce Partnership to Enhance Patient Outcomes through Digital Drug Delivery Technology
–Electronic Microchip-Based Implant Technology Delivers Medicines over Months and Years, Improving Adherence and Compliance for Patients
–Promising Innovative Technology Offers Potential Across Therapeutic Areas and Disease States
Jerusalem, and Lexington, MA, June 18, 2015 – Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) and Microchips Biotech, Inc. today announced that they have entered into a partnership under which the companies will explore innovative ways to apply Microchips Biotech’s implantable drug delivery device to Teva’s portfolio of products with the goal of enhancing clinical outcomes for patients on chronic drug therapies. Continue reading Microchips Biotech

